Search

Your search keyword '"Lookstein, Robert"' showing total 743 results
Start Over Author "Lookstein, Robert"
743 results on '"Lookstein, Robert"'

2. Editor's Choice – Development and Testing of Step, Error, and Event Frameworks to Evaluate Technical Performance in Peripheral Endovascular Interventions

Author

Goncalves, Frederico Bastos, Baumgartner, Iris, Bilhim, Tiago, Bisdas, Theodosios, Bismuth, Jean, Brodmann, Marianne, Castriota, Fausto, Cieri, Enrico, Deloose, Koen, Dias, Nuno, Diehm, Nicolas, Ferraresi, Roberto, Haskal, Ziv J., Hinchliffe, Robert, Kayssi, Ahmed, Leal Lorenzo, Jose Ignacio, Lookstein, Robert, Morgan, Robert, Müller-Hülsbeck, Stefan, Mustapha, Jihad, Nienaber, Christoph Anton, Papia, Guiseppe, Patel, Ashish, Prasad, Anand, Stavroulakis, Konstatinos, Reijnen, Michel, Rundback, John, van den Berg, Jos C., Soenens, Gilles, Gorden, Lauren, Doyen, Bart, Wheatcroft, Mark, de Mestral, Charles, Palter, Vanessa, and Van Herzeele, Isabelle

Published
2024
Full Text
View/download PDF

3. Radioembolization plus Immune Checkpoint Inhibitor Therapy Compared with Radioembolization plus Tyrosine Kinase Inhibitor Therapy for the Treatment of Hepatocellular Carcinoma

Author

Garcia-Reyes, Kirema, Gottlieb, Ricki A., Menon, Kartikeya M., Bishay, Vivian, Patel, Rahul, Patel, Rajesh, Nowakowski, Scott, Sung, Max W., Marron, Thomas U., Gansa, William H., Zhang, Jack, Raja, Sahitya C., Shilo, Daniel, Fischman, Aaron, Lookstein, Robert, and Kim, Edward

Published
2024
Full Text
View/download PDF

6. Arterial Revascularization

Author

Ali, Ibrahim, Arslan, Bulent, Beasley, Robert, Bechara, Carlos, Berens, Pauline, Chandra, Venita, Chohan, Omar, Cote, Claudia, Dadrass, Farnaz, Dhand, Sabeen, Dua, Anahita, Elmasri, Fakhir, Fischer, Bryan, Hallak, Ahmad Omar, Han, Daniel K., Heaney, Carmen, Herman, Kevin, Jaffer, Uman, Jessula, Samuel, Kayssi, Ahmed, Keefe, Nicole, Khurana, Neal, Kohi, Maureen, Korff, Ricki A., Krishnan, Prakash, Kumar, Abhishek, Laurich, Chad, Lookstein, Robert A., Madassery, Sreekumar, Maringo, Alison, Martin, Jesse, Mathews, S. Jay, McCon, Reuben Perez, Mehta, Ankit, Melton, Jim G., Miranda, Jorge, Mize, Abigail, Baker, Miguel Montero, Mustapha, Jihad A., Nagi, Mohamed, N’Dandu, Zola, Osman, Murat, Parsons, Blake P., Posham, Raghuram, Raja, Aishwarya, Riaz, Rehan, Richard, Michele, Rundback, John H., Saab, Fadi A., Salazar, Gloria, Schiro, Brian J., Secemsky, Eric, Sommerset, Jill, Tabriz, David M., Taylor, Jordan, Thomas, Anish, Tummala, Srini, Tummala, Venkat, Uddin, Omar M., Van Den Berg, Jos, Watts, Micah, Wiechmann, Bret N., Ysa, August, Madassery, Sreekumar, editor, and Patel, Aesha, editor

Published
2023
Full Text
View/download PDF

14. Abstract 15011: Recent Trends in Interventional Treatment of Acute Pulmonary Embolism and Their Implications for a National Healthcare System

Author

Mohr, Katharina, Farmakis, Ioannis T, Barco, Stefano, Channick, Richard N, Christodoulou, Konstantinos, Giri, Jay S, Hobohm, Lukas, Keeling, Brent, Keller, Karsten, Lanno, Michelle, Lookstein, Robert A, Moriarty, John M, Reed, Jamie, Rosovsky, Rachel P, Rosenfield, Kenneth, Secemsky, Eric A, Todoran, Thomas M, Binder, Harald, and Konstantinides, Stavros V

Published
2023
Full Text
View/download PDF

19. Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia

Author

Conte, Michael S, Bradbury, Andrew W, Kolh, Philippe, White, John V, Dick, Florian, Fitridge, Robert, Mills, Joseph L, Ricco, Jean-Baptiste, Suresh, Kalkunte R, Murad, M Hassan, Aboyans, Victor, Aksoy, Murat, Alexandrescu, Vlad-Adrian, Armstrong, David, Azuma, Nobuyoshi, Belch, Jill, Bergoeing, Michel, Bjorck, Martin, Chakfé, Nabil, Cheng, Stephen, Dawson, Joseph, Debus, Eike S, Dueck, Andrew, Duval, Susan, Eckstein, Hans H, Ferraresi, Roberto, Gambhir, Raghvinder, Gargiulo, Mauro, Geraghty, Patrick, Goode, Steve, Gray, Bruce, Guo, Wei, Gupta, Prem C, Hinchliffe, Robert, Jetty, Prasad, Komori, Kimihiro, Lavery, Lawrence, Liang, Wei, Lookstein, Robert, Menard, Matthew, Misra, Sanjay, Miyata, Tetsuro, Moneta, Greg, Prado, Jose A Munoa, Munoz, Alberto, Paolini, Juan E, Patel, Manesh, Pomposelli, Frank, Powell, Richard, Robless, Peter, Rogers, Lee, Schanzer, Andres, Schneider, Peter, Taylor, Spence, De Ceniga, Melina V, Veller, Martin, Vermassen, Frank, Wang, Jinsong, Wang, Shenming, and GVG Writing Group for the Joint Guidelines of the Society for Vascular Surgery, European Society for Vascular Surgery

Subjects
Prevention, Clinical Research, Clinical Trials and Supportive Activities, Cardiovascular, Patient Safety, Good Health and Well Being, Endovascular Procedures, Global Burden of Disease, Humans, International Cooperation, Ischemia, Limb Salvage, Lower Extremity, Peripheral Arterial Disease, Practice Guidelines as Topic, Prevalence, Quality of Life, Severity of Illness Index, Societies, Medical, Specialties, Surgical, Treatment Outcome, Chronic limb-threatening ischemia, Critical limb ischemia, Peripheral artery disease, Diabetes, Foot ulcer, Endovascular intervention, Bypass surgery, Practice guideline, Evidence-based medicine, GVG Writing Group for the Joint Guidelines of the Society for Vascular Surgery (SVS), European Society for Vascular Surgery (ESVS), and World Federation of Vascular Societies, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Cardiovascular System & Hematology
Abstract

Guideline summaryChronic limb-threatening ischemia (CLTI) is associated with mortality, amputation, and impaired quality of life. These Global Vascular Guidelines (GVG) are focused on definition, evaluation, and management of CLTI with the goals of improving evidence-based care and highlighting critical research needs. The term CLTI is preferred over critical limb ischemia, as the latter implies threshold values of impaired perfusion rather than a continuum. CLTI is a clinical syndrome defined by the presence of peripheral artery disease (PAD) in combination with rest pain, gangrene, or a lower limb ulceration >2 weeks duration. Venous, traumatic, embolic, and nonatherosclerotic etiologies are excluded. All patients with suspected CLTI should be referred urgently to a vascular specialist. Accurately staging the severity of limb threat is fundamental, and the Society for Vascular Surgery Threatened Limb Classification system, based on grading of Wounds, Ischemia, and foot Infection (WIfI) is endorsed. Objective hemodynamic testing, including toe pressures as the preferred measure, is required to assess CLTI. Evidence-based revascularization (EBR) hinges on three independent axes: Patient risk, Limb severity, and ANatomic complexity (PLAN). Average-risk and high-risk patients are defined by estimated procedural and 2-year all-cause mortality. The GVG proposes a new Global Anatomic Staging System (GLASS), which involves defining a preferred target artery path (TAP) and then estimating limb-based patency (LBP), resulting in three stages of complexity for intervention. The optimal revascularization strategy is also influenced by the availability of autogenous vein for open bypass surgery. Recommendations for EBR are based on best available data, pending level 1 evidence from ongoing trials. Vein bypass may be preferred for average-risk patients with advanced limb threat and high complexity disease, while those with less complex anatomy, intermediate severity limb threat, or high patient risk may be favored for endovascular intervention. All patients with CLTI should be afforded best medical therapy including the use of antithrombotic, lipid-lowering, antihypertensive, and glycemic control agents, as well as counseling on smoking cessation, diet, exercise, and preventive foot care. Following EBR, long-term limb surveillance is advised. The effectiveness of nonrevascularization therapies (eg, spinal stimulation, pneumatic compression, prostanoids, and hyperbaric oxygen) has not been established. Regenerative medicine approaches (eg, cell, gene therapies) for CLTI should be restricted to rigorously conducted randomizsed clinical trials. The GVG promotes standardization of study designs and end points for clinical trials in CLTI. The importance of multidisciplinary teams and centers of excellence for amputation prevention is stressed as a key health system initiative.

Published
2019

26. Developmental or Procedural Vena Cava Interruption and Venous Thromboembolism: A Review.

Author

Bikdeli, Behnood, Sadeghipour, Parham, Lou, Junyang, Bejjani, Antoine, Khairani, Candrika D., Rashedi, Sina, Lookstein, Robert, Lansky, Alexandra, Vedantham, Suresh, Sobieszczyk, Piotr, Mena-Hurtado, Carlos, Aghayev, Ayaz, Henke, Peter, Mehdipoor, Ghazaleh, Tufano, Antonella, Chatterjee, Saurav, Middeldorp, Saskia, Wasan, Suman, Bashir, Riyaz, and Lang, Irene M.

Subjects
VENAE cavae, THROMBOEMBOLISM, VENA cava superior, VENOUS thrombosis, RIGHT heart atrium
Abstract

The inferior vena cava (IVC) and superior vena cava are the main conduits of the systemic venous circulation into the right atrium. Developmental or procedural interruptions of vena cava might predispose to stasis and deep vein thrombosis (DVT) distal to the anomaly and may impact the subsequent rate of pulmonary embolism (PE). This study aimed to review the various etiologies of developmental or procedural vena cava interruption and their impact on venous thromboembolism. A systematic search was performed in PubMed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines per each clinical question. For management questions with no high-quality evidence and no mutual agreements between authors, Delphi methods were used. IVC agenesis is the most common form of congenital vena cava interruption, is associated with an increased risk of DVT, and should be suspected in young patients with unexpected extensive bilateral DVT. Surgical techniques for vena cava interruption (ligation, clipping, and plication) to prevent PE have been largely abandoned due to short-term procedural risks and long-term complications, although survivors of prior procedures are occasionally encountered. Vena cava filters are now the most commonly used method of procedural interruption, frequently placed in the infrarenal IVC. The most agreed-upon indication for vena cava filters is for patients with acute venous thromboembolism and coexisting contraindications to anticoagulation. Familiarity with different forms of vena cava interruption and their local and systemic adverse effects is important to minimize complications and thrombotic events. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Development and Testing of Step, Error, and Event Frameworks to Evaluate Technical Performance in Peripheral Endovascular Interventions

Author

Soenens, Gilles, primary, Gorden, Lauren, additional, Doyen, Bart, additional, Wheatcroft, Mark, additional, de Mestral, Charles, additional, Palter, Vanessa, additional, Van Herzeele, Isabelle, additional, Bastos Goncalves, Frederico, additional, Baumgartner, Iris, additional, Bilhim, Tiago, additional, Bisdas, Theodosios, additional, Bismuth, Jean, additional, Brodmann, Marianne, additional, Castriota, Fausto, additional, Cieri, Enrico, additional, Deloose, Koen, additional, Dias, Nuno, additional, Diehm, Nicolas, additional, Ferraresi, Roberto, additional, Haskal, Ziv J., additional, Hinchliffe, Robert, additional, Kayssi, Ahmed, additional, Leal Lorenzo, Jose Ignacio, additional, Lookstein, Robert, additional, Morgan, Robert, additional, Müller-Hülsbeck, Stefan, additional, Mustapha, Jihad, additional, Nienaber, Christoph Anton, additional, Papia, Guiseppe, additional, Patel, Ashish, additional, Prasad, Anand, additional, Stavroulakis, Konstatinos, additional, Reijnen, Michel, additional, Rundback, John, additional, and van den Berg, Jos C., additional

Published
2024
Full Text
View/download PDF

29. Modelling Costs of Interventional Pulmonary Embolism Treatment: Implications of US Trends for a European Healthcare System

Author

Mohr, Katharina, primary, Keeling, Brent, additional, Kaier, Klaus, additional, Neusius, Thomas, additional, Rosovsky, Rachel P, additional, Moriarty, John M, additional, Rosenfield, Kenneth, additional, Abele, Christina, additional, Farmakis, Ioannis T, additional, Keller, Karsten, additional, Barco, Stefano, additional, Channick, Richard N, additional, Giri, Jay S, additional, Lookstein, Robert A, additional, Todoran, Thomas M, additional, Christodoulou, Konstantinos C, additional, Hobohm, Lukas, additional, Lanno, Michelle, additional, Reed, Jamie, additional, Binder, Harald, additional, Konstantinides, Stavros V, additional, Valerio, Luca, additional, and Secemsky, Eric A, additional

Published
2024
Full Text
View/download PDF

32. Intravascular ultrasound use in peripheral arterial and deep venous interventions: Multidisciplinary expert opinion from SCAI/AVF/AVLS/SIR/SVM/SVS

Author

Secemsky, Eric A., primary, Aronow, Herbert D., additional, Kwolek, Christopher J., additional, Meissner, Mark, additional, Muck, Patrick E., additional, Parikh, Sahil A., additional, Winokur, Ronald S., additional, George, Jon C., additional, Salazar, Gloria, additional, Murphy, Erin H., additional, Costantino, Mary M., additional, Zhou, Wei, additional, Li, Jun, additional, Lookstein, Robert, additional, and Desai, Kush R., additional

Published
2024
Full Text
View/download PDF

37. Aortic Aneurysm and Stent Graft Assessment

Author

Livshits, Ilya, Lekperic, Safet, Lookstein, Robert, Kauczor, Hans-Ulrich, Series Editor, Parizel, Paul M., Series Editor, Peh, Wilfred C. G., Series Editor, Brady, Luther W., Honorary Editor, Lu, Jiade J., Series Editor, Nikolaou, Konstantin, editor, Bamberg, Fabian, editor, Laghi, Andrea, editor, and Rubin, Geoffrey D., editor

Published
2019
Full Text
View/download PDF

40. Evaluation and Treatment of Patients With Lower Extremity Peripheral Artery Disease Consensus Definitions From Peripheral Academic Research Consortium (PARC)

Author

Patel, Manesh R, Conte, Michael S, Cutlip, Donald E, Dib, Nabil, Geraghty, Patrick, Gray, William, Hiatt, William R, Ho, Mami, Ikeda, Koji, Ikeno, Fumiaki, Jaff, Michael R, Jones, W Schuyler, Kawahara, Masayuki, Lookstein, Robert A, Mehran, Roxana, Misra, Sanjay, Norgren, Lars, Olin, Jeffrey W, Povsic, Thomas J, Rosenfield, Kenneth, Rundback, John, Shamoun, Fadi, Tcheng, James, Tsai, Thomas T, Suzuki, Yuka, Vranckx, Pascal, Wiechmann, Bret N, White, Christopher J, Yokoi, Hiroyoshi, and Krucoff, Mitchell W

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Clinical Trials and Supportive Activities, Angioplasty, Atherectomy, Blood Vessel Prosthesis, Constriction, Pathologic, Diagnostic Imaging, Endarterectomy, Humans, Lower Extremity, Patient Outcome Assessment, Peripheral Arterial Disease, Quality of Life, Severity of Illness Index, Stents, Walking, amputation, foot, intermittent claudication, leg, myocardial infarction, stroke, myocardial infarction, Cardiorespiratory Medicine and Haematology, Public Health and Health Services, Cardiovascular System & Hematology, Cardiovascular medicine and haematology
Abstract

The lack of consistent definitions and nomenclature across clinical trials of novel devices, drugs, or biologics poses a significant barrier to accrual of knowledge in and across peripheral artery disease therapies and technologies. Recognizing this problem, the Peripheral Academic Research Consortium, together with the U.S. Food and Drug Administration and the Japanese Pharmaceuticals and Medical Devices Agency, has developed a series of pragmatic consensus definitions for patients being treated for peripheral artery disease affecting the lower extremities. These consensus definitions include the clinical presentation, anatomic depiction, interventional outcomes, surrogate imaging and physiological follow-up, and clinical outcomes of patients with lower-extremity peripheral artery disease. Consistent application of these definitions in clinical trials evaluating novel revascularization technologies should result in more efficient regulatory evaluation and best practice guidelines to inform clinical decisions in patients with lower extremity peripheral artery disease.

Published
2015

43. The RAVI registry: prospective, multicenter study of radial access in embolization procedures – 30 days follow up.

Author

Guimaraes, Marcelo, Fischman, Aaron, Yu, Hyeon, Tasse, Jordan, Stewart, Jessica, Pereira, Keith, Uflacker, Andre, Yamada, Ricardo, Vaheesan, Kirubahara, Malik, Ali Abdullah, Sherwani, Afsheen, Commander, Clayton, Kohi, Maureen, Lookstein, Robert, Nowakowski, Francis, Patel, Rahul, Patel, Rajesh, Titano, Joseph, and Ranade, Mona

Abstract

Background: There is a lack of registry studies about transradial access (TRA) outcomes. This prospective registry evaluated the TRA and procedure outcomes of visceral embolizations performed via TRA with 30-day follow-up. Material & methods: Prospective, multicenter registry included uterine fibroids (UFE), prostate artery (PAE), liver tumors (LT), and other hypervascular tumors (OHT) embolization performed in six US hospitals. Between February 2020 and January 2022, 99 patients underwent one radial artery visceral intervention (RAVI); 70 had UFE (70.7%), 16 PAE (16.2%), 7 LT (7.1%), and 6 OHT (6.1%). The mean age was 50.1 (±11.1) years, and 74/99 (74.7%) were females. The primary safety endpoints included hand ischemia, stroke, and death. Procedural success was defined as completing the intended procedure via radial artery (RA) access. Technical success was defined as the successful delivery of HydroPearl™ microspheres and complete embolization of the target vessel. Results: Procedural and technical successes were 100% and 97%, respectively. There was no stroke, hand ischemia, radial-to-femoral conversion, access-related serious adverse events, or clinically evident radial artery occlusion at 30 days. There were two deaths: one respiratory failure and one progression of liver disease. Minor RA-related adverse event included arterial spasm, hematoma, and post-procedure discomfort. Conclusion: This prospective, multicenter, open-label registry confirmed the high safety profile and effectiveness of radial access in UFE, PAE, LT, and OHT embolization procedures without stroke, hand ischemia, or access-related serious adverse events at 30-day follow-up. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results